EDS‐FLU: An important step in appropriate medical therapy for chronic rhinosinusitis with nasal polyps.

Inasmuch as this limited evidence raised corticosteroid irrigation to a "strong recommendation", surely the Grade A evidence in NAVIGATE I/II should earn EDS-FLU a "strong recommendation" for use as a component of appropriate medical treatment, particularly after inadequate response to standard INCS treatment. Corticosteroid use, irrigations, medical therapy for chronic rhinosinusitis, rhinosinusitis, sinusitis, topical therapies for chronic rhinosinusitis Keywords: corticosteroid use; irrigations; medical therapy for chronic rhinosinusitis; rhinosinusitis; sinusitis; topical therapies for chronic rhinosinusitis EN corticosteroid use irrigations medical therapy for chronic rhinosinusitis rhinosinusitis sinusitis topical therapies for chronic rhinosinusitis 893 895 3 05/17/22 20220601 NES 220601 The International Consensus Statement on Allergy and Rhinology: Rhinosinusitis 2021 (ICAR-RS-2021) provides important updates on new therapies that have become available since 2016.1 As authors of the NAVIGATE I and II studies, we bring to your attention an apparent misunderstanding regarding controlled clinical trials that evaluated the efficacy and safety of the exhalation delivery system with fluticasone (EDS-FLU; XHANCE SP ® sp ) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). [Extracted from the article]